Usage and dosage of ivonib/ivitinib

Ivosidenib/Ivosidenib is used to treat certain types of blood cell cancers (acute myeloid leukemia-AML, myelodysplastic syndrome-MDS); it is also used to treat cholangiocarcinoma. Ivonib works by slowing the growth of cancer cells and by helping a patient's bone marrow grow normal blood cells, so the patient will need fewer blood transfusions.

When using ivonib, patients need to follow the doctor's instructions. The usually recommended dose is 500 mg once daily.It is administered orally. It can be taken before or after meals, but it should be noted that the drug should not be taken with a high-fat meal to avoid affecting the absorption of the drug. Ivonib tablets should be swallowed whole. Do not crush, chew, or break the tablets. Doing so may change the release characteristics of the drug, thereby affecting its efficacy.

For patients with AML or MDS who do not have disease progression or unacceptable toxicity it is recommended that ivonib be continued for at least 6 months. This cycle is designed to ensure that patients have sufficient time to observe clinical response, as tumor response often takes time to manifest. In addition, it is crucial to regularly monitor the patient's blood indicators and possible side effects during treatment so that the treatment plan can be adjusted in a timely manner.

In patients with newly diagnosedAML, ivonib is often used in combination with azacitidine. This combination therapy was administered on days 1-7 (or days 1-5 and 8-9) of each 28-day cycle. Azacitidine can be administered subcutaneously or intravenously, and the specific dosing schedule and dosage should be adjusted based on the patient's specific condition and the recommendations of the physician.

Patients treated with ivonib need to be aware that although the drug has certain anti-tumor effects, it may also be associated with some side effects, such as nausea, fatigue, abnormal liver function, etc. Therefore, patients should maintain communication with their doctors during treatment and report any symptoms of discomfort in a timely manner.